Clinical trials: Cholangitis, open to volunteers
Biliary Atresia, Kasai Portoenterostomy Status, Cholangitis
Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Cholangitis Post Kasai in Biliary Atresia)
Biliary atresia is a rare liver disease affecting newborns. In those babies bile ducts are blocked, and bile cannot flow from the liver to the intestines.
- Trial name
- TRACK-BA (NCT07129655)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Geneva
Primary Biliary Cholangitis
National Database on Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a rare, autoimmune, cholestatic liver disease. No data about the disease epidemiology exist in Italy.
- Trial name
- PBC322 (NCT05151809)
- Testing
- Clinical information
- Where
- 55 sites in Italy
- Volunteers
- 6,000 people
- Sponsor
- University of Milano Bicocca
PSC
PET/MRI of Primary Sclerosing Cholangitis
This study aims to use positron emission tomography (PET)/magnetic resonance imaging (MRI) to diagnose and quantify PSC-related biliary tract fibrosis and to improve upon the currently available non-invasive diagnostic…
- Trial name
- NCT06252610
- Testing
- Radiotracer Injection, Contrast Media, Magnetic Resonance, Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Healthy Volunteers, Primary Sclerosing Cholangitis
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
The main aim of this study is to see if the drug TAK-781 is safe for healthy volunteers and for participants with PSC. The study will also look at how well participants can tolerate TAK-781.
- Trial name
- NCT07229911
- Testing
- TAK-781
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Takeda
PSC
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.
- Trial name
- WIND-PSC (NCT06297993)
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 2,000 people
- Sponsor
- PSC Partners Seeking a Cure
Primary Biliary Cholangitis
Monitoring the Response of Combination Ursodiol and Seladelpar Treatment
This study aims to provide comprehensive insights into the therapeutic effects of combination treatment with ursodiol and seladelpar in PBC patients by assessing biochemical responses using biomarkers such as ALP and total…
- Trial name
- NCT07122206
- Testing
- Blood Draws
- Volunteers
- 100 people
- Sponsor
- Methodist Health System
Primary Biliary Cholangitis (PBC)
A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics
About 1/3 of patients with primary biliary cholangitis (PBC) exhibit moderate to severe interface hepatitis, and this group of patients have poor response to UDCA treatment.
- Trial name
- NCT06591468
- Testing
- Prednisone, UDCA (Ursodeoxycholic acid)
- Where
- 2 sites in China
- Volunteers
- 244 people
- Sponsor
- Han Ying
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition.
- Trial name
- DRIVE-UP (NCT07341282)
- Testing
- Vancomycin (blinded), Vancomycin (open-label extension)
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- McMaster University
Chronic Hepatic Pruritus, Cholestatic Liver Disease
Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
The purpose of this research is to investigate the efficacy of nemolizumab in the treatment of adults with moderate to severe chronic hepatic pruritus.
- Conditions
- Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis
- Trial name
- NCT07843420
- Testing
- Nemolizumab-ilto
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Primary Biliary Cholangitis (PBC)
FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
The goal of this clinical trial is to learn if the drug Fenofibrate works to treat adults with a liver disease called Primary Biliary Cholangitis (PBC) who have not received previous treatment.
- Trial name
- NCT07296458
- Testing
- Fenofibrate, UDCA (Ursodeoxycholic acid)
- Where
- 2 sites in China
- Volunteers
- 132 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Cholecystectomy, Gallbladder
EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study
Cholecystectomy is considered the standard definitive treatment after an acute biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis).
- Conditions
- Cholecystectomy, Gallbladder, Endoscopic Ultrasound (EUS), Cholelithiasis
- Trial name
- DRECON (NCT07655778)
- Testing
- EUS-guided gallbladder drainage (EUS-GBD), Conservative management (CM)
- Volunteers
- 110 people
- Sponsor
- Hospital Mutua de Terrassa
Primary Sclerosing Cholangitis, Liver Transplant, Complications
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort…
- Conditions
- Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
- Trial name
- NCT06905054
- Testing
- Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Primary Sclerosing Cholangitis (PSC)
Biodegradable Stents in Primary Sclerosing Cholangitis
In patients with PSC, endoscopic therapy of strictures aims to improve cholestasis by relieving the biliary obstruction via endoscopic biliary dilatation with consideration of plastic stents in strictures refractory to dilatation…
- Trial name
- BSTPSC (NCT07607353)
- Testing
- archimedes stent
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College Hospital NHS Trust
Cholangitis, Sclerosing, PSC
Swiss Primary Sclerosing Cholangitis Cohort Study
Research project in which biological material is sampled and health-related personal data is further used and collected. Coded data are used.
- Conditions
- Cholangitis, Sclerosing, PSC, Primary Sclerosing Cholangitis (PSC)
- Trial name
- NCT03146936
- Where
- 21 sites in Switzerland
- Volunteers
- 120 people
- Sponsor
- Fondazione Epatocentro Ticino
Primary Biliary Cholangitis (PBC)
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)
- Trial name
- NCT06755541
- Testing
- Fenofibrate in Combination With Ursodeoxycholic Acid
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis
The goal of this clinical trial is to learn how oral vancomycin therapy may contribute in treating paediatric inflammatory bowel disease, particularly atypical ulcerative colitis and PSC-associated colitis.
- Conditions
- Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), Pediatric Inflammatory Bowel Diseases
- Trial name
- VERDA (NCT07646223)
- Testing
- Oral Vancomycin
- Where
- Finland
- Volunteers
- 140 people
- Sponsor
- Tampere University Hospital
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cholestatic Liver Disease
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease
- Trial name
- NCT06825559
- Testing
- Saroglitazar Magnesium 1 mg
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Zydus Therapeutics Inc.
Primary Biliary Cholangitis
Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC).
- Trial name
- NCT05749822
- Testing
- Fenofibrate 200mg, UDCA
- Where
- 12 sites in China
- Volunteers
- 104 people
- Sponsor
- Xijing Hospital of Digestive Diseases